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[a]
Introduction
Human African trypanosomiasis (HAT) is a serious health prob-
lem in sub-Saharan Africa, with an estimated 50000 new cases
each year. HAT, a fatal disease unless treated, is caused by the
protozoan parasites Trypanosoma brucei gambiense and
T. b. rhodesiense, which initially reside within the blood stream
and then subsequently penetrate into the central nervous
system giving rise to the classical symptoms of HAT. The cur-
rent drugs to treat HAT are inadequate due to poor efficacy,
side effects and the requirement for parenteral administration,
which is not appropriate for a rural African setting.
[1,2]
Herein we report a target-based approach to the discovery
of novel inhibitors of trypanothione reductase (TryR) as a po-
tential therapy for HAT. TryR is an NADPH-dependent flavopro-
tein disulphide oxidoreductase unique to, and essential for
growth of, trypanosomatid parasites, whose function is to con-
vert trypanothione disulphide (N
1,N
8-bis(glutathionyl)spermi-
dine disulphide, T[S]2; Figure 1) into the physiologically rele-
vant reduced dithiol (T[SH]2).
[3] In these parasites, T[SH]2 serves
as a substitute for many of the metabolic and antioxidant func-
tions ascribed to glutathione (GSH) in mammalian cells.
[4] Mam-
malian glutathione reductase (GR) is the nearest homologue to
TryR. However, the host and parasite enzymes have significant
differences in their active site architecture resulting in a pro-
nounced ability to discriminate between their respective disul-
phide substrates. These features make TryR an attractive target
for selective drug design.
[5]
Before carrying out a drug discovery programme TryR was
assessed for appropriateness using the traffic light scoring
system that we recently described.
[6] The process assesses a
target in terms of: level of validation (genetic and chemical),
assay feasibility, potential for toxicity and resistance, druggabil-
ity, and level of structural information available allowing cross
target comparisons and prioritisation for entry into hit discov-
ery programmes. The results of this exercise are illustrated in
Table 1. In brief, there was sufficient supporting information in
the areas of genetic and chemical validation, assay feasibility
and protein structure to progress the target into hit discovery.
The main area for caution for this target was druggability since
the active site is rather large and featureless.
There is an urgent need for new drugs for the treatment of
tropical parasitic diseases such as human African trypanoso-
miasis, which is caused by Trypanosoma brucei. The enzyme
trypanothione reductase (TryR) is a potential drug target
within these organisms. Herein we report the screening of a
62000 compound library against T. brucei TryR. Further work
was undertaken to optimise potency and selectivity of two
novel-compound series arising from the enzymatic and whole
parasite screens and mammalian cell counterscreens. Both of
these series, containing either a quinoline or pyrimidinopyra-
zine scaffold, yielded low micromolar inhibitors of the enzyme
and growth of the parasite. The challenges of inhibiting TryR
with druglike molecules is discussed.
Figure 1. The structure of trypanothione and the principle of the DTNB-cou-
pled assay for TryR.
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MEDA number of different TryR inhibitors have been reported in
the literature. These can be broadly classified as tricyclics,
[7]
polyamine analogues,
[5f,h,8] redox inhibitors,
[9] substrate ana-
logues,
[10] and compounds identified through screening of a li-
brary of druglike compounds.
[11] To our knowledge, none of
these series have progressed beyond the early discovery
phase.
Results and Discussion
Hit discovery
In order to discover novel lead compounds against TryR, a
high-throughput screen of an in-house designed diverse com-
pound library
[12] (62000 compounds) was performed.
A nonenzymatically coupled colourimetric method for de-
tecting TryR activity as developed by Fairlamb et al.
[13] was em-
ployed. In this assay, the activity of TryR is coupled to the re-
duction of DTNB (5,5’-dithiobis[2-nitrobenzoic acid]) by T(SH)2
to form the yellow thionitrobenzoate anion (TNB
 ) (see
Figure 1). Unlike the direct assay, this method increases assay
sensitivity, and allows the assay to proceed in a linear fashion
for extended time periods with T[S]2 concentrations at or
below Km.
The TryR screening assay was miniaturised to a 384-well
plate format and optimised to the standard required to sup-
port a large-scale screening campaign. The assay was assessed
for robustness in an automated environment yielding the fol-
lowing typical performance statistics: Z’=0.84 0.001; %CV
(plate)=3.65 0.4; S:B=10 0.25; IC50 (clomipramine)=12.4 
0.14 mm. Clomipramine was used as a standard throughout the
screening process.
TryR was initially screened in single-point mode at 30 mm
and the percentage inhibition (PI) value calculated for each
compound (Figure 2). The distribution of hits deviated from
normality due to a shoulder of activity between 20 and 50 PI,
indicating a capacity of TryR to bind with a low affinity to a
range of diverse structures. A statistical assessment of the
screen relative to the error around the full signal controls (5 
standard deviations) indicated that PI values  42% should be
considered as highly significant. All compounds yielding PI
 50% were therefore selected for re-testing in duplicate
(30 mm). A total of 767 compounds were confirmed as hits
giving a confirmation rate (primary to re-test screen) of 84%
and an overall confirmed hit rate of 1.24%.
A preliminary chemistry assessment of the confirmed hits
identified a selection of 120 compounds for potency determi-
nations. Each compound was subjected to a ten-point half-log
titration in duplicate ranging from 30 mm to 1 nm. In all cases,
residual material from the potency compound plates was sub-
jected to LCMS analysis for structure and purity confirmation.
Figure 3 illustrates the ability of this assay to report reliable po-
tency values for test compounds, yielding a correlation coeffi-
Table 1. Antiparasitic drug target evaluation for trypanothione reductase.
Criteria Status Comments
Assay feasibility green Recombinant enzyme available in large quantities. 96 well assay in place
Genetic/chemical
validation
green Target essential in trypanosomes as evidenced by conditional knock-out.
[3] Some chemical validation from inhibitors such
as trivalent antimonials and melaminophenyl arsenicals.
Druggability amber Several published low micromolar low molecular weight inhibitors. The active site of TryR is large and therefore the
identification of potent low molecular weight inhibitors could be an issue.
Potential for resistance amber TryR is a single copy gene in T. brucei and no reported gene amplification in response to inhibitors has been reported.
Reversal of competitive inhibitors by accumulation of T[S]2 is a potential liability
Potential for toxicity green Significant differences in substrate specificity and structure of TryR to corresponding human homologue, glutathione
reductase.
Protein structural
information
green Crystal structures of recombinant T.cruzi TryR, alone and in combination with substrates and a covalently linked inhibitor
Figure 2. Single-point screen percentage inhibition (PI) distribution against
TryR for all compounds returning PI values  50 (n=901).
Figure 3. pIC50 correlation between two replicate assays.
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2) value of 0.967 between replicate pIC50 determina-
tions.
Analysis of the potency data for the best hits revealed multi-
ple putative hit series covering a range potencies from 0.7 to
30 mm. Key compounds were resynthesised or resupplied to
further confirm their activity and identity. From the five series
initially identified, two were deemed of sufficient interest to
progress into formal hit validation. The aim of this phase was
to rapidly assess the existence of defined structure–activity re-
lationships (SAR), whilst securing a significant increase (>10-
fold) in activity over the initial hit compound.
Hit series 1
Series 1 was based on a quinoline scaffold, which afforded a
number of possible points of variation: the 5-methylfuran in
the 2-position, the amide in the 4-position, and the 6-bromo
substituent. To expand the SAR, we prepared or purchased 84
analogues. Table 2 provides data on the most potent and sig-
nificant inhibitors.
The general synthetic route is shown in Scheme 1. In brief,
the indoline-2,3-dione was reacted with an appropriate ketone
to give the quinoline. The carboxylic acid could then be con-
densed with appropriate amines to form the required amides.
A summary of the SAR is given in Figure 4. Essentially, any
variation of the 5-methylfuran at the 2-position led to a de-
crease in activity (1 and 17, 20 and 22; 8 and 13; 12 and 18);
in the 4-position, amides with a basic substituent, such as di-
methylaminoethyl were more potent than neutral aryl or alky-
laryl amides (15, 23, 24, 25); and the 6-bromo group could be
moved around the ring without too much effect on the activity
(1, 9, 10). Although replacing the 6-bromo substituent with a
chloro atom led to a small effect on activity (1 and 8, 16), re-
placement of the 6-bromo with hydrogen or fluorine led to
loss in activity (1 and 12; 4 and 14, 1 and 26). Particularly with
substituents on the 4-position, increases in MW and clogP led
to small increases in potency, suggestive of a general surface
contact between inhibitors and protein. There may be a similar
effect with the 6-bromo group,
as changes in location to the 7-
or 8-position of the quinoline
ring system, or even replacing it
with a chlorine, led to only
small effects on activity. It was
difficult to deduce which
changes, if any, would increase
potency at these positions. It is
possible that the 5-methylfuran
at the 2-position is making a
very specific hydrogen bonding
and/or p-stacking interaction,
which accounts for the require-
ment for this group at this posi-
tion.
Hit series 2
Series 2, containing the pyrimi-
dopyridazines scaffold, gave five
compounds with an inhibition
of >62% in the initial screen.
The general synthetic route is
outlined in Scheme 2. The sub-
stituted 6-chlorouracil starting
material was made by conden-
sation of the appropriately sub-
stituted urea with malonic acid,
followed by chlorination. The
chloride was displaced with an
appropriate hydrazine. The hy-
Table 2. Activity of series 1 (compounds 1–26) against TryR.
Compd R
1 R
2 R
3 R
4 TryR
IC50 [mm]
1 CH2CH2NMe2 6-Br 5’-Methyl-furan-2-yl H 1.7
2 CH2CH2NHMe 6-Br 5’-Methyl-furan-2-yl H 1.1
3 CH2CH2NMe3+ 6-Br 5’-Methyl-furan-2-yl H 1.2
4 CH2CH2-N-morpholine 6-Br 5’-Methyl-furan-2-yl H 4.2
5 2-pyridyl methyl 6-Br 5’-Methyl-furan-2-yl H 4.7
6 3-pyridyl 6-Br 5’-Methyl-furan-2-yl H 7.2
7 CH2CH2CH2-N-imidazole 6-Br 5’-Methyl-furan-2-yl H 5.1
8 CH2CH2NMe2 6-Cl 5’-Methyl-furan-2-yl H 3.1
9 CH2CH2NMe2 7-Br 5’-Methyl-furan-2-yl H 5.7
10 CH2CH2NMe2 8-Br 5’-Methyl-furan-2-yl H 5.8
11 2-pyridyl methyl H 5’-Methyl-furan-2-yl H 12.1
12 CH2CH2NMe2 H5 ’-Methyl-furan-2-yl H 14.4
13 CH2CH2NMe2 6-Cl 4’-Methylphenyl CH3 26.5
14 CH2CH2-N-morpholine H 5’-Methyl-furan-2-yl H 100
15 CH2Ph 6-Br 5’-Methyl-furan-2-yl H >100
16 CH2CH2 CH2-N-morpholine 6-Cl 5’-Methyl-furan-2-yl H 11.6
17 CH2CH2NMe2 6-Br 3’-Methoxyphenyl H >100
18 CH2CH2NMe2 6-Br Phenyl H >100
19 CH2C6H4-p-SO2NH2 6-Br 5’-Methyl-furan-2-yl H 8.4
20 CH2CH2NMe2 6-Br Furan-2-yl H 32.4
21 CH2CH2NMe2 6-Br Pyrid-4-yl H 96.3
22 CH2CH2NMe2 6-Br 5’-Methyl-thiophen-2-yl H >100
23 -N-morpholine 6-Br 5’-Methyl-furan-2-yl H >100
24 CH2-furan-2-yl 6-Br 5’-Methyl-furan-2-yl H >100
25 CH2CH2Ph 6-Br 5’-Methyl-furan-2-yl H >100
26 CH2CH2NMe2 6-F 5’-Methyl-furan-2-yl H >100
Scheme 1. Synthetic route for hit series 1. Reagents and conditions:
a) Ketone, KOH, EtOH/H2O, 1108C, 12 min, mW; b) R
1NH2, CDI, CH2Cl2,R T ,
18 h.
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and cyclisation was achieved by treatment with sodium nitrite
followed by dehydration through microwave heating in DMF
with molecular sieves to give 42.
[14] The free NH could be alky-
lated with various alkyl bromides to give the desired product.
In total ~30 compounds from this series were assayed. Table 3
provides data on the most potent and significant inhibitors. A
summary of the SAR is given in Figure 5.
Small alkyl groups were required in positions R
1 (methyl)
and R
2 (methyl and ethyl) as replacement of R
2 or both R
1 and
R
2 with hydrogen led to a loss in activity (42 and 43). The
methyl at R
2 could be replaced by a small alkyl group; howev-
er, replacement with larger alkyl groups led to a decrease in
activity. A number of different aromatic substituents were tol-
erated at R
3, however, there was no clear SAR.
Selectivity and mode of action studies
The selectivity of these series with respect to nearest human
homologue of TryR was assessed in glutathione reductase (GR)
assays. Both TryR and GR assays were performed with sub-
strate concentrations equal to Km allowing direct comparison
of IC50 values for selectivity assessment. All of the compounds
tested demonstrated significant selectivity for TryR over GR
(Table 4). This is not surprising if we assume our binding model
is correct as the binding site in GR is smaller, less hydrophobic
and less negatively charged than that of TryR. Hence, if our
compounds are binding by a general hydrophobic interaction
and interaction with negatively charged residues in the active
site, they are unlikely to interact with GR.
Mode of inhibition studies were carried out on key represen-
tatives of series 1 and 2. The data indicated that neither com-
pound series acted as simple linear competitive inhibitors with
respect to T[S]2. The mixed inhibition of compounds in series 1
indicates the compounds can either bind to the free enzyme
or to the enzyme–substrate complex, implying that the com-
pounds are not binding in an orientation that excludes binding
Figure 4. SAR for hit series 1.
Table 3. Activity of series 2 (compounds 31–44) against TryR.
Compd R
1 R
2 R
3 TryR
IC50 [mm]
39 Me Me 4’-Methylphenyl 8.6
40 Me CH2CH3 Thiophen-2-yl 12.8
41 Me CH2CH3 2’-Fluoro-5’-Bromophenyl 10.2
42 Me H 2’-Fluoro-5’-Bromophenyl >100
43 HH 2 ’-Fluoro-5’-Bromophenyl 92
44 Me CH2CH3 Pyridine-3-yl >100
45 Me CH2CH3 4’-Bromothiophen-2-yl 13.0
46 Me CH2CH3 4’-Trifluoromethylphenyl 15.2
47 Me CH2CH3 Phenyl 11.3
48 Me CH2CH2NMe2 2’-Fluoro-5’-Bromophenyl >100
49 Me CH2CH3 CH=CHC6H5 2.6
50 Me CH(CH3)2 2’-Fluoro-5’-Bromophenyl >50
51 Me (CH2)3CH3 2’-Fluoro-5’-Bromophenyl >100
52 Me cyclopentyl 2’-Fluoro-5’-Bromophenyl >100
Figure 5. SAR for hit series 2.
Scheme 2. Synthetic Route for hit series 2. Reagents and conditions:
a) H2NNHMe, EtOH, 808C, 1 h; b) ArCOH, EtOH, 808C, 2 h; c) NaNO2, AcOH,
0!208C, 16 h; d) DMF, 908C, 2 h; e) R
2Br, Cs2CO3,8 08C, 3 h, DMF.
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competitive, with compounds binding only to the enzyme–
substrate complex. In enzymes such as TryR that obey a bi bi
ping pong reaction mechanism, such an inhibition pattern can
arise due to an inhibitor competing for the second independ-
ent substrate-binding site, NADPH. However, a similar uncom-
petitive inhibition pattern was observed when the concentra-
tion of the second substrate, NADPH, was varied in the pres-
ence of a fixed concentration of T[S]2. This finding indicates
that compounds from series 2 bind at a site distinct from both
substrate-binding sites. Since compounds of series2 have
some structural similarity to the FAD co-factor of TryR, we pro-
pose that disruption of the orientation or displacement of FAD
could account for the uncompetitive inhibition pattern. In
theory, both series present significant advantages over com-
petitive inhibitors where build up of substrate trypanothione
during inhibition in vivo could reduce the efficacy of the inhibi-
tor. Indeed, substrate build-up in the case of uncompetitive
inhibition may even drive binding of the inhibitor.
The most potent compounds were also assessed for their
ability to affect T. brucei and MRC-5 (prototypical mammalian
cell line) proliferation in vitro (Table 4). Series 1 compounds
showed weak inhibition of parasite growth. Whilst it is expect-
ed that cellular activity is likely to be lower than enzyme activi-
ty due to factors such as high intracellular substrate concentra-
tion, there was no clear correlation between enzyme inhibition
and effect on trypanosomes. In the case of series 2, the cellular
activity was more potent than would be predicted by the
enzyme assay suggesting that these compounds are either se-
lectively concentrated by the parasites or are acting off-target.
However, the latter seems more likely, given the lack of selec-
tivity apparent between the trypanosome and MRC-5 read-
outs.
Conclusions
We have reported the identifi-
cation of two novel compound
series active against TryR in vi-
tro from a high-throughput
screening campaign. Both hit
series were low molecular
weight compounds with lead-
like properties suitable for a
medicinal chemistry optimisa-
tion programme. They are
structurally very different to
other TryR inhibitors reported
in the literature and constitute
novel chemical lead structures
against TryR.
SAR studies were undertaken
for both series. For series 1,
there was some discernable
SAR. Unfortunately, we were
unable to significantly increase
the potency of the compounds
against the enzyme to a level likely to have therapeutic signifi-
cance. The TryR active site contains both hydrophobic and
acidic regions (for interaction with the spermidine moiety); it is
likely that what we are observing is hydrophobic interactions
between the hydrophobic regions of our inhibitors and the
active site and electrostatic interactions between the positive
charge on the inhibitors and the negatively charged region of
the active site. In order to get a significant increase in potency,
it will be necessary to build in some additional specific interac-
tions between the inhibitor and the enzyme. This process
would be greatly aided by a co-crystal structure of an inhibitor
bound in the active site. Some cellular activity was observed,
which implies that the compounds are able to penetrate into
cells. However we believe that to get a significant correlation
between enzyme and cellular activity will require enzyme
inhibitors that are significantly more potent.
Data from the gene knockout studies indicated that it would
be necessary to cause >90% loss in activity of TryR for cell
death to occur.
[3] Therefore, either a very potent inhibitor (low
nanomolar) of the enzyme is required or some kind of irreversi-
ble inhibition. Furthermore, the TryR active site is large and rel-
atively solvent exposed, which may make the discovery of low
molecular weight, highly potent, competitive inhibitors prob-
lematic, especially in the absence of structural information
from inhibitors bound into the active site.
In summary, we have identified two novel series of TryR in-
hibitors from a HTS screen and have carried out SAR studies.
Further work is needed to increase the potency of these com-
pounds to a level where the activity is sufficient to achieve sig-
nificant cellular activity. This would be greatly facilitated by
structural information.
Table 4. Selectivity of hit compounds and mode of inhibition.
[a]
Compd Mode of inhibiton Inhibitor constants [mm]I C 50 [mm]E C 50 [mm]
Ki Ki’ TryR hGR
[b] Parasite
[c] MRC-5
[c]
1 linear mixed 1.6 0.2 3.2 0.3 1.7 >100 10.3 >50
2 NT
[d] – – 1.1 NT 6.0 18.7
3 NT – – 1.2 NT >50 >50
4 linear mixed 3.0 0.2 4.3 0.3 4.2 74.2 25.6 >50
5 linear mixed 2.0 0.1 3.0 0.2 4.7 33.4 18.7 31.1
6 NT – – 7.2 NT 6.9 NT
7 NT – – 5.1 NT 16.5 NT
10 NT – – 5.8 NT 19.2 NT
12 NT – – 14.4 NT 32.1 43.7
19 NT – – 8.4 NT 14.5 NT
39 linear uncompetitive 4.6 0.3 (T[S]2)
29.4 1.7 (NADPH)
– 8.6 >100 1.22 1.62
40 linear uncompetitive 3.0 0.2 (T[S]2)
21.5 1.6 (NADPH)
– 12.8 10.0 1.43 3.2
41 NT – – 10.2 NT 8.1 NT
45 NT – – 13.0 NT 3.4 12.9
[a] MOI: Compounds 1–19 are from hit series 1 and 39–45 from hit series 2. [b] hGR: human glutathione reduc-
tase. [c] Concentration giving 50% growth inhibition after 73 h exposure. [d] NT: not tested.
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Biology
Enzyme-based assays
Primary screening assay for TryR
Recombinant TryR from T. brucei was initially screened for inhibitors
in single-point mode. Each test compound (500 nL) was transferred
into 384-well clear polystyrene plates at an appropriate stock con-
centration. Clomipramine and DMSO were added to the appropri-
ate control wells. Then 37.5 mL of reaction mix (3 nm TryR, 6 mm
T[S]2,5 0mm DTNB, 40 mm Hepes, 1 mm EDTA, pH 7.4) was added
to each well and the reaction initiated by addition of 150 mm
NADPH (4 mL). Low signal controls received no NADPH. Plates were
incubated for 35 min at room temperature and absorbance mea-
sured at 405 8 nm using the Envision platereader (Perkin–Elmer).
Initial single-point screening of compounds was conducted at
30 mm; subsequent ten-point screening was conducted between
30 mm and 1 nm or between 100 mm and 3 nm depending on stock
concentrations. The final DMSO level was 1% in all cases.
Mode of inhibition studies
An assay mixture consisting of TryR, NADPH and DTNB was made
up in 40 mm HEPES; 1 mm EDTA, pH 7.4. Assay mixture (180 mL)
containing three different concentrations of test compound was
added to three rows of a microtitre plate, a fourth row contained
only the assay mixture. The test compound concentration ranged
up to ~1 IC 50 value. T[S]2 was serially diluted across a fifth row of
the plate to produce a 12-point range from 500 mm to 5.8 mm. The
assay was initiated by transferring 20 mL of the T[S]2 row to each of
the assay rows. The final 200 mL assay contained 150 mm NADPH;
50 mm DTNB and 20 mUmL
 1 U TryR.
Reaction rates were measured from the linear increase in absorb-
ance at 412 nm using a Molecular Devices Thermomax plate
reader. Individual data sets were plotted as 1/v versus 1/[S] using
Grafit 5.0 (Erithacus software) and inspected for diagnostic inhibi-
tion patterns. Data sets were then globally fitted by nonlinear re-
gression to the appropriate equation for competitive, mixed or un-
competitive inhibition.
Cell-based assays
Measurement of the ability of the compounds to inhibit trypano-
some (bloodstream form T. brucei brucei single marker) and human
(MRC5, human lung fibroblast cells) cell growth was performed
using a modification of the cell viability assay previously described
by Raz et al.
[15]
Trypanosome growth assay
Cell culture plates were stamped with 1mL of an appropriate stock
concentration of test compound, followed by addition of 200 mL
trypanosome culture (HMI9-T,
[16] 10% FCS) to each well at a density
of 2000 cells per well (except column 12 receiving media only).
MRC-5 growth assay
MRC-5 cells (2000 cells per well) were seeded in 200 mL DMEM,
10% FCS and allowed to adhere overnight. One microlitre of test
compound was added to each well on the day of assay initiation.
Trypanosome and MRC-5 plates were incubated at 378C in an at-
mosphere of 5% CO2 for 69 h, prior to the addition of 20 mL reza-
surin (final concentration 50 mm). After a further 4 h, fluorescence
was measured (excitation 528 nm; emission 590 nm) using a
BioTek flx800 plate reader.
For cell assays, ten-point screening was conducted between 15 mm
and 0.5 nm or between 50 mm and 2 nm, depending on stock con-
centrations. The final DMSO level was 0.5% in all cases.
Chemistry
1H NMR were recorded on either a Bruker Avance DPX 500 or on a
Bruker Avance 300 spectrometer. Chemical shifts (d) are expressed
in ppm. Signal splitting patterns are described as singlet (s), dou-
blet (d), triplet (t), quartet (q), multiplet (m), broad (br), or combi-
nation thereof. Low resolution electrospray (ES) mass spectra were
recorded on a Bruker MicroTof mass spectrometer, run in positive
ion mode, using either CH3OH, CH3OH/H2O (95:5) or H2O/CH3CN
(1:1) + 0.1% formic acid as the mobile phase. High resolution elec-
trospray measurements were performed on a Bruker MicroTof mass
spectrometer. LC-MS analysis was performed using an Agilent
HPLC 1100 with a diode array detector in parallel with a Bruker Mi-
croTof mass spectrometer. A Phenomenex Gemini C18 column
110 A 50 3.0 mm, 5 mm particle size was used. The mobile phase
was H2O/CH3CN + 0.1% HCOOH (80:20!5:95 over 3.5 min, 5:95
for 1.5 min; flow rate 0.5 mLmin
 1).
Thin layer chromatography (TLC) was carried out on Merck silica
gel 60 F254 plates using UV light and/or KMnO4 for visualisation.
Column chromatography was performed using RediSep  4 or 12 g
silica prepacked columns with the specified eluent system.
Compounds 6, 7, 13, 16, 17, 19, 21, 23 and 24 were purchased
from ChemBridge and compounds 18, 39, 40, 41, 44, 45, 46, 47
and 49 were purchased from ASINEX and submitted to the screen-
ing assay. They were checked for purity by LCMS and were found
to be >90% pure.
All reactions were carried out under dry and inert conditions
unless otherwise stated.
6-Bromo-N-(2-(dimethylamino)ethyl)-2-(5-methylfuran-2-yl)qui-
noline-4-carboxamide (1): Compound 27 (200 mg, 0.6 mm) and
carbonyldiimidazole (CDI; 108 mg, 0.66 mm) were stirred in CH2Cl2
(15 mL) at 358C for 20 min. N,N-dimethylethane-1,2-diamine
(58 mg, 0.66 mm) was added, and the solution stirred at RT for
18 h. The solution was diluted with CH2Cl2 (30 mL) and washed
with aq NaHCO3 (2 20 mL), H2O (1 30 mL) and brine (2 20 mL).
The organic layer was dried (MgSO4), filtered and concentrated to
afford a yellow/brown solid. The crude product was purified by
flash column chromatography (6%, CH3OH/CH2Cl2) to give 1 as
pale yellow solid (65 mg, 27%):
1H NMR (500 MHz, [D6]DMSO): d=
2.28 (6H, br s, 2CH3), 2.44 (3H, s, CH3), 2.51 (2H, m, CH2), 3.46 (2H,
q, J=6.3 Hz, CH2), 6.39 (1H, m, ArH), 7.38 (1H, d, J=3.2 Hz, ArH),
7.91 (1H, d, J=2.2 Hz, ArH), 7.92 (1H, m, ArH), 7.96 (1H, m, ArH),
8.4 (1H, d, J=2.2 Hz, ArH), 8.85 ppm (1H, br s, NH); LCMS (ES+):
m/z (%): 402 (100) [M+H]
+ (
79Br), 404 (100) [M+H]
+ (
81Br); tR=
5.0 min.
6-Bromo-N-(2-(methylamino)ethyl)-2-(5-methylfuran-2-yl)quino-
line-4-carboxamide (2): Prepared as for 1 from 27 (150 mg,
0.45 mm) and CDI (82 mg, 0.5 mm)i nC H 2Cl2 (15 mL). The mixture
was stirred at 358C for 20 min, then treated with N-methylethane-
1,2-diamine (37 mg, 0.5 mm) and stirred at RT for 18 h. The resul-
tant solid product was collected by filtration and further purified
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solid (37 mg, 21%):
1H NMR (500 MHz, [D6]DMSO): d=2.29 (3H, s,
CH3), 2.40 (3H, s, CH3), 2.72 (2H, m, CH2), 3.41 (2H, m, CH2), 6.39
(1H, br s, ArH), 7.37 (1H, s, ArH), 7.89 (1H, dd J=9.0 and 2.2 Hz,
ArH), 7.96 (2H, m, 2ArH), 8.34 (1H, d, J=2.1 Hz, ArH), 8.88 ppm
(1H, br s, NH); LCMS (ES+): m/z (%): 388 (100) [M+H]
+ (
79Br), 390
(100) [M+H]
+ (
81Br); tR=4.2 min.
6-Bromo-N,N,N-trimethyl-2-(2-(5-methylfuran-2-yl)quinoline-4-
carboxamido)ethanaminium iodide (3):C H 3I (31 mg, 0.22 mm)
was added to a solution of 1 (60 mg, 0.15 mm) in dry acetone
(5 mL). The solution was stirred at RT for 48 h then concentrated. A
solid was precipitated from the resulting gum on the addition of
acetone (15 mL), which was isolated by filtration and washed with
acetone (3 10 mL) to afford 3 as a beige solid (50 mg, 61%):
1H NMR (500 MHz, [D6]DMSO): d=2.41 (3H, s, 2CH3), 3.19 (9H, s,
3CH3), 3.6 (2H, m, CH2), 3.79 (2H, m, CH2), 6.39 (1H, br s, ArH), 7.36
(1H, m, ArH), 7.94 (1H, dd, J=9.0, 2.2 Hz, ArH), 7.98 (2H, m, 2ArH),
8.34 (1H, d, J=2.0 Hz, ArH), 9.25 ppm (1H, br s, NH); LCMS (ES+):
m/z (%): 418 (100) [M+H]
+ (
79Br), 420 (100) [M+H]
+ (
81Br); tR=
4.4 min.
6-Bromo-2-(5-methylfuran-2-yl)-N-(2-morpholinoethyl)quinoline-
4-carboxamide (4): Prepared as for 1 from 27 (150 mg, 0.45 mm),
CH2Cl2 (15 mL), CDI (82 mg, 0.5 mm) and 2-morpholinoethanamine
(65 mg, 0.5 mm). The reaction was stirred for 18 h then concentrat-
ed. The crude solid was recrystallised from refluxing EtOAc to give
4 as a white crystalline solid (95 mg, 48%):
1H NMR (500 MHz,
[D6]DMSO): d=2.38 (3H, s, CH3), 2.48 (2H, m, CH2), 2.49 (4H, m,
2CH2), 4.49 (2H, m, CH2), 4.66 (4H, m, 2CH2), 6.39 (1H, m, ArH), 7.38
(1H, d, J=3.2 Hz, ArH), 7.91 (1H, d, J=2.2 Hz, ArH), 7.92 (1H, m,
ArH), 7.96 (1H, m, ArH), 8.32 (1H, d, J=2.0 Hz, ArH), 8.86 ppm (1H,
br s, NH); LCMS (ES+): m/z (%): 444 (100) [M+H]
+ (
79Br), 446 (100)
[M+H]
+ (
81Br); tR=4.5 min.
6-Bromo-2-(5-methylfuran-2-yl)-N-(pyridin-2-ylmethyl)quinoline-
4-carboxamide (5): Prepared as for 1 from 27 (150 mg, 0.45 mm),
CDI (82 mg, 0.5 mm) and pyrin-2-ylmethanamine (55 mg, 0.5 mm).
The reaction was stirred for 18 h then concentrated. The crude
solid was purified by trituration with hot Et2O (3 10 mL) to give 5
as pale yellow solid (70 mg, 37%):
1H NMR (500 MHz, [D6]DMSO):
d=2.39 (3H, s, CH3), 4.79 (2H, m, CH2), 6.39 (1H, br s, ArH), 7.35
(1H, dd, J=6.7, 5.0 Hz, ArH), 7.41 (1H, d, J=3.3 Hz, ArH), 7.49 (1H,
d, J=7.8 Hz, ArH), 7.84 (1H, dt, J=7.7, 1.8 Hz, ArH), 7.92 (1H, dd,
J=9.0, 2.2 Hz, ArH), 7.99 (1H, d, J=9.0 Hz, ArH), 8.03 (1H, s, ArH),
8.52 (1H, s, ArH), 8.61 (1H, m, ArH), 9.51 ppm (1H, br s, NH); LCMS
(ES+): m/z (%): 422 (100) [M+H]
+ (
79Br), 424 (100) [M+H]
+ (
81Br);
tR=4.7 min.
6-Chloro-N-(2-(dimethylamino)ethyl)-2-(5-methylfuran-2-yl)qui-
noline-4-carboxamide (8): Compound 29 (468 mg, 1.63 mm) and
CDI (260 mg, 1.8 mm) were stirred in CH2Cl2 (15 mL) for 10 min at
RT. N,N-Dimethylethane-1,2-diamine (158 mg, 1.8 mm) was added,
and the resulting solution was stirred at RT for 18 h. The reaction
was diluted with CH2Cl2 (20 mL) and washed with aq NaHCO3 (2 
20 mL), H2O (2 30 mL) and brine (1 50 mL). The organic layer
was dried (MgSO4), filtered and concentrated in vacuo. Purification
by flash column chromatography (2%, CH3OH/CH2Cl2) gave 8 as a
white solid (200 mg, 34%):
1H NMR (500 MHz, [D6]DMSO): d=2.26
(6H, s, 2CH3), 2.41 (3H, s, CH3), 2.48 (2H, m, CH2), 3.47 (2H, m, CH2),
6.39 (1H, br s, ArH), 7.34 (1H, br s, ArH), 7.77 (1H, m, ArH), 7.90
(1H, br s, ArH), 7.96 (1H, dd, J=9.0, 2.2 Hz, ArH), 8.1 (1H, br s,
ArH), 8.84 ppm (1H, br s, NH); LCMS (ES+): m/z (%): 358 [M+H]
+;
tR=5.0 min.
7-Bromo-N-(2-(dimethylamino)ethyl)-2-(5-methylfuran-2-yl)qui-
noline-4-carboxamide (9): Prepared as for 1 from 31 (265 mg,
0.8 mm), CH2Cl2 (15 mL), CDI (144 mg, 0.88 mm) and N,N-dimethyl-
ethane-1,2-diamine (77 mg, 0.66 mm). The reaction was stirred at
RT for 18 h. Purification by flash column chromatography (3%,
CH3OH/CH2Cl2) gave 9 as a white solid (85 mg, 38%):
1H NMR
(300 MHz, CDCl3): d=2.3 (6H, s, 2CH3), 2.45 (3H, s, CH3), 2.68 (2H,
t, J=5.8 Hz, CH2), 3.70 (2H, q, J=5.4 Hz, CH2), 6.21 (1H, m, ArH),
7.35 (2H, m, ArH), 7.92 (1H, s, ArH), 8.05 (1H, m, ArH), 8.16 ppm
(1H, m, ArH); LCMS (ES+): m/z (%): 402 (100) [M+H]
+ (
79Br), 404
(100) [M+H]
+ (
81Br); tR=5.1 min.
8-Bromo-N-(2-(dimethylamino)ethyl)-2-(5-methylfuran-2-yl)qui-
noline-4-carboxamide (10): Prepared as for 1 from 32 (200 mg,
0.6 mm), CH2Cl2 (10 mL), CDI (108 mg, 0.66 mm) and N,N-dimethyl-
ethane-1,2-diamine (58 mg, 0.66 mm). The reaction was stirred for
18 h at RT. Purification by flash column chromatography (3%,
CH3OH/CH2Cl2) gave 10 as a white solid (60 mg, 25%):
1H NMR
(500 MHz, [D6]DMSO): d=2.24 (6H, s, 2CH3), 2.43 (3H, s, CH3), 2.8
(2H, m, CH2), 3.46 (2H, m, CH2), 6.40 (1H, br s, ArH), 7.38 (1H, d,
J=3.3 Hz, ArH), 7.47 (1H, m, ArH), 7.91 (1H, s, ArH), 8.12 (1H, dd,
J=8.4, 1.2 Hz, ArH), 8.17 (1H, dd, J=7.5, 1.2 Hz, ArH), 8.84 ppm
(1H, br t, NH); LCMS (ES+): m/z (%): 402 (100) [M+H]
+ (
79Br), 404
(100) [M+H]
+ (
81Br); tR=5.2 min.
2-(5-Methylfuran-2-yl)-N-(pyridin-2-ylmethyl)quinoline-4-carbox-
amide (11): Compound 34 (100 mg, 0.4 mm) and CDI (72 mg,
0.44 mm) were dissolved in CH2Cl2 (4 mL). The solution was stirred
for 10 min at RT, then pyrin-2-ylmethanamine (48 mg, 0.44 mm)
was added. The reaction was stirred at RT for 48 h and worked up
as previously described (see details for 8). The product was recrys-
tallised from from Et2O to give 11 as a white solid (80 mg, 58%):
1H NMR (500 MHz, [D6]DMSO): d=2.44 (3H, br s, CH3), 4.68 (2H, m,
CH2), 6.39 (1H, m, ArH), 7.31 (1H, m, ArH), 7.35 (1H, m, ArH), 7.48
(1H, d, J=7.8 Hz, ArH), 7.6 (1H, ddd, J=8.2, 6.9, 1.2 Hz, ArH), 7.80
(1H, ddd, J=8.4, 6.9, 1.4 Hz, ArH), 7.85 (1H, dt, J=7.7, 1.8 Hz, ArH),
7.97 (1H, s, ArH), 8.05 (1H, d, J=8.0 Hz, ArH), 8.16 (1H, m, ArH),
8.58 (1H, ddd, J=4.8, 1.6 and 0.8 Hz, ArH), 9.47 ppm (1H, br s,
NH); LCMS (ES+): m/z (%): 344 [M+H]
+; tR=4.7 min.
N-(2-(Dimethylamino)ethyl)-2-(5-methylfuran-2-yl)quinoline-4-
carboxamide (12): Prepared as for 11 from 34 (100 mg, 0.4 mm),
8m L C H 2Cl2, CDI (72 mg, 0.44 mm) and N,N-dimethylaminoethyl-
enediamine (39 mg, 0.44 mm). The reaction was stirred for 18 h at
RT. Column chromatography (5%, CH3OH/CH2Cl2) gave 12 as a
white solid (30 mg, 24%):
1H NMR (500 MHz, [D6]DMSO): d=2.22
(6H, s, 2CH3), 2.41 (3H, s, CH3), 2.48 (2H, m, CH2), 3.46 (2H, m, CH2),
6.39 (1H, m, ArH), 7.32 (1H, d, J=3.3 Hz, ArH), 7.59 (1H, ddd, J=
8.2, 6.9, 1.2 Hz, ArH), 7.78 (1H, ddd, J=8.4, 6.9, 1.4 Hz, ArH), 7.86
(1H, s, ArH), 8.03 (1H, d, J=8.4 Hz, ArH), 8.11 (1H, m, ArH),
8.8 ppm (1H, br s, NH); LCMS (ES+): m/z (%): 324 [M+H]
+; tR=
4.3 min.
2-(5-Methylfuran-2-yl)-N-(2-morpholinoethyl)quinoline-4-carbox-
amide (14): Prepared as for 11 from 34 (150 mg, 0.6 mm), 10 mL
CH2Cl2, CDI (108 mg, 0.66 mm) and 2-morpholinoethanamine
(86 mg, 0.66 mm). The reaction was stirred for 18 h at RT, concen-
trated and purified by triturating the crude solid with hot Et2Ot o
give 14 (50 mg, 23%):
1H NMR (500 MHz, [D6]DMSO): d=2.41 (3H,
s, CH3), 2.48 (4H, m, 2CH2), 2.52 (2H, m, CH2), 3.49 (2H, q, J=
6.5 Hz, CH2), 3.64 (4H, t, J=4.4 Hz, 2CH2), 6.39 (1H, m, ArH), 7.34
(1H, d, J=3.3 Hz, ArH), 7.59 (1H, ddd, J=8.2, 6.9, 1.2 Hz, ArH), 7.79
(1H, ddd, J=8.4, 6.9, 1.4 Hz, ArH), 7.85 (1H, s, ArH), 8.05 (1H, d, J=
8.4 Hz, ArH), 8.18 (1H, m, ArH), 8.79 ppm (1H, br s, NH); LCMS
(ES+): m/z (%): 366 [M+H]
+; tR=4.1 min.
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amide (15): Prepared as for 1 from 27 (150 mg, 0.45 mm), CH2Cl2
(10 mL), CDI (82 mg, 0.5 mm) and benzylamine (54 mg, 0.5 mm).
The reaction was stirred for 18 h at RT. Flash column chromatogra-
phy (2%, CH3OH/CH2Cl2) gave 15 as a beige solid (16 mg, 8%):
1H NMR (500 MHz, CDCl3): d=2.36 (3H, s, CH3), 4.70 (2H, d, J=
5.7 Hz, CH2), 6.09 (1H, m, ArH), 6.59 (1H, br s, NH), 6.95 (1H, m,
ArH), 7.31 (1H, m, ArH), 7.39 (4H, m, 4ArH), 7.58 (1H, s, ArH), 7.66
(1H, dd, J=9.0, 2.1 Hz, ArH), 7.74 (1H, d, J=9.0 Hz, ArH), 8.2 ppm
(1H, d, J=2.1 Hz, ArH); LCMS (ES+): m/z (%): 421 (100) [M+H]
+
(
79Br), 423 (100) [M+H]
+ (
81Br); tR=5.7 min.
6-Bromo-N-(2-(dimethylamino)ethyl)-2-(furan-2-yl)quinoline-4-
carboxamide (20): Prepared as for 1 from 33 (200 mg, 0.63 mm),
CH2Cl2 (15 mL), CDI (115 mg, 0.7 mm) and N,N-dimethylethane-1,2-
diamine (62 mg, 0.7 mm). The reaction was stirred at RT for 18 h.
Flash column chromatography (6%, CH3OH/CH2Cl2) gave 20 as a
pale yellow solid (65 mg, 27%):
1H NMR (500 MHz, [D6]DMSO): d=
2.29 (6H, br s, 2CH3), 2.51 (2H, m, CH2), 3.48 (2H, q, J=6.5 Hz, CH2),
6.78 (1H, m, ArH), 7.47 (1H, m, ArH), 7.95 (1H, dd, J=9.0, 2.2 Hz,
ArH), 7.99 (3H, m, 3ArH), 8.44 (1H, d, J=2.2 Hz, ArH), 8.9 ppm (1H,
br s, NH); LCMS (ES+): m/z (%): 388 (100) [M+H]
+ (
79Br), 390 (100)
[M+H]
+ (
81Br); tR=4.9 min.
6-Bromo-N-(2-(dimethylamino)ethyl)-2-(5-methylthiophen-2-yl)-
quinoline-4-carboxamide (22): Prepared as for 11 from 30
(209 mg, 0.6 mm), CH2Cl2 (15 mL), CDI (108 mg, 0.66 mm) and N,N-
dimethylethane-1,2-diamine (58 mg, 0.66 mm). The reaction was
stirred for 18 h at RT. Flash column chromatography (3%, CH3OH/
CH2Cl2) gave 22 as a beige solid (73 mg, 29%):
1H NMR (500 MHz,
[D6]DMSO): d=2.28 (6H, br s, 2CH3), 2.44 (3H, s, CH3), 2.60 (2H, m,
CH2), 3.50 (2H, q, J=6.3 Hz, CH2), 6.92 (1H, br s, ArH), 7.76 (1H, m,
ArH), 7.89 (2H, m, 2ArH), 8.11 (1H, s, ArH), 8.40 (1H, d, J=2.1 Hz,
ArH), 8.9 ppm (1H, m, NH); LCMS (ES+): m/z (%): 419 (100) [M+
H]
+ (
79Br), 421 (100) [M+H]
+ (
81Br); tR=5.1 min.
6-bromo-2-(5-methylfuran-2-yl)-N-phenethylquinoline-4-carbox-
amide (25): Prepared as for 1 from 27 (200 mg, 0.6 mm), CH2Cl2
(10 mL), CDI (108 mg, 0.66 mm) and phenethylamine (84 mL,
0.66 mm). The reaction was stirred for 18 h at RT. Purification by
flash column chromatography (3%, CH3OH/CH2Cl2) gave 25 as a
cream solid (58 mg, 28%):
1H NMR (500 MHz, CDCl3): d=2.43 (3H,
s, CH3), 4.70 (2H, d, J=5.7 Hz, CH2), 5.23 (2H, m, CH2), 6.11 (1H, m,
ArH), 6.58 (1H, m, ArH), 6.97 (1H, d, J=3.3 Hz, ArH), 7.31 (1H, m,
ArH), 7.61 (3H, m, 3ArH), 7.61 (1H, s, ArH), 7.66 (1H, dd, J=9.0,
2.1 Hz, ArH), 7.74 (1H, d, J=9.0 Hz, ArH), 8.21 ppm (1H, d, J=
2.1 Hz, ArH); LCMS (ES+): m/z (%): 434 (100) [M+H]
+ (
79Br), 436
(100) [M+H]
+ (
81Br); tR=5.2 min.
N-(2-(dimethylamino)ethyl)-6-fluoro-2-(5-methylfuran-2-yl)quino-
line-4-carboxamide (26): Prepared as for 1 from 28 (150 mg,
0.55 mm), CH2Cl2 (10 mL), CDI (90 mg, 0.61 mm) and N,N-dimethyl-
ethane-1,2-diamine (54 mg, 0.61 mm). The reaction was stirred for
18 h at RT. Purification by flash column chromatography (3%,
CH3OH/CH2Cl2) gave 26 as a white solid (50 mg, 24%):
1H NMR
(500 MHz, [D6]DMSO): d=2.29 (6H, br s, 2CH3), 2.46 (3H, s, CH3),
2.53 (2H, m, CH2), 3.46 (2H, q, J=6.5 Hz, CH2), 6.37 (1H, dd, J=3.3,
1.0 Hz, ArH), 7.34 (1H, d, J=3.3 Hz, ArH), 7.72 (1H, m, ArH), 7.92
(1H, br s, ArH), 7.95 (1H, dd, J=10.4, 2.9 Hz, ArH), 8.1 (1H, dd, J=
9.3, 5.6 Hz, ArH), 8.85 ppm (1H, m, NH); LCMS (ES+): m/z (%): 341
[M+H]
+; tR=4.0 min.
6-Bromo-2-(5-methylfuran-2-yl)quinoline-4-carboxylic acid (27):
A solution of 5-bromoindoline-2,3-dione (1.25 g, 5 mm) in EtOH/
H2O (20 mL, 1:1) in a 30 mL microwave reactor tube was treated
with 1-(5-methylfuran-2-yl)ethanone (0.62 g, 5 mm). This tube was
transferred to the microwave reactor and, following a 1 min pre-
stirring, was heated to 1108C for 13 min. The reaction mixture was
acidified to pH 3 using AcOH, diluted with H2O (60 mL) and ex-
tracted with EtOAc (2 80 mL). The organic layer was washed with
H2O (2 80 mL) and brine (80 mL), dried (MgSO4), filtered and con-
centrated to give a yellow/brown solid. The crude product was re-
dissolved in a minimum amount of hot EtOAc (~40 mL) and the
pure product was allowed to crystallise out yielding 27 (500 mg,
30%): RF=0.1 (10%, CH3OH/CH2Cl2);
1H NMR (500 MHz, [D6]DMSO):
d=2.42 (3H, br s, CH3), 6.40 (1H, dd, J=3.3, 0.9 Hz, ArH), 7.39 (1H,
d, J=3.3 Hz, ArH), 7.83 (1H, dd, J=9.0, 2.4 Hz, ArH), 8.07 (1H, d,
J=9.0 Hz, ArH), 8.31 (1H, s, ArH), 8.77 (1H, d, J=2.4 Hz, ArH),
14.16 ppm (1H, br s, COOH); LCMS (ES+): m/z (%): 332 (100)
[M+H]
+ (
79Br), 334 (100) [M+H]
+ (
81Br); tR=0.5–0.6 min.
6-Fluoro-2-(5-methylfuran-2-yl)quinoline-4-carboxylic acid (28):
Prepared as for 27 from 5-fluoroindoline-2,3-dione (0.94 g,
5.51 mm), 1-(5-methylfuran-2-yl)ethanone (0.65 mL, 6.06 mm) and
KOH (2.8 g, 50 mm) in EtOH/H2O (20 mL, 1:1) to give 28 as a pale
cream solid (600 mg, 40%):
1H NMR (500 MHz, [D6]DMSO): d=2.45
(3H, br s, CH3), 6.40 (1H, m, ArH), 7.40 (1H, d, J=3.3 Hz, ArH), 7.94
(1H, dd, J=9.0, 2.2 Hz, ArH), 8.00 (1H, d, J=8.9 Hz, ArH), 8.31 (1H,
s, ArH), 8.92 (1H, d, J=2.1 Hz, ArH), 14.10 ppm (1H, br s, COOH);
LCMS (ES+): m/z (%): 271 [M+H]
+; tR=0.5–0.6 min.
6-Chloro-2-(5-methylfuran-2-yl)quinoline-4-carboxylic acid (29):
Prepared as for 27 from 5-chloroindoline-2,3-dione (1 g, 5.51 mm),
1-(5-methylfuran-2-yl)ethanone (0.65 mL, 6.06 mm) and KOH (2.8 g,
50 mm) in EtOH/H2O (20 mL, 1:1) to give 29 as a pale cream solid
(600 mg, 38%):
1H NMR and LCMS confirm purity at >95%;
1H NMR (500 MHz, [D6]DMSO): d=2.42 (3H, br s, CH3), 6.40 (1H, br
d, J=3.2 Hz, ArH), 7.39 (1H, d, J=3.3 Hz, ArH), 7.94 (1H, dd, J=2.2,
9.0 Hz, ArH), 8.00 (1H, d, J=8.9 Hz, ArH), 8.3 (1H, s, ArH), 8.92 (1H,
m, ArH), 14.15 ppm (1H, br s, COOH); LCMS (ES+): m/z (%): 288
[M+H]
+; tR=0.5–0.6 min.
6-Bromo-2-(5-methylthiophen-2-yl)quinoline-4-carboxylic acid
(30): Prepared as for 27 from 2-acetyl-5-methylthiophene (0.77 g,
5.5 mm) to give carboxylic acid 30 as a yellow solid (1.08 g, 62%):
1H NMR and LCMS confirm purity at >95%;
1H NMR (500 MHz,
[D6]DMSO): d=2.47 (3H, br s, CH3), 6.92 (1H, m, ArH), 7.92 (3H, m,
3ArH), 8.42 (1H, s, ArH), 8.88 (1H, br s, ArH), 14.15 ppm (1H, br s,
COOH); LCMS (ES+): m/z (%): 348 (100) [M+H]
+ (
79Br), 350 (100)
[M+H]
+ (
81Br); tR=0.5–0.6 min.
7-Bromo-2-(5-methylfuran-2-yl)quinoline-4-carboxylic acid (31):
Prepared as for 27 from 6-bromoindoline-2,3-dione (1 g, 3.3 mm).
The crude product was triturated with hot Et2O to isolate purified
carboxylic acid 31 as a pale brown solid (350 mg, 36%):
1H NMR
and LCMS confirm purity at >95%;
1H NMR (500 MHz, [D6]DMSO):
d=2.42 (3H, s, CH3), 6.40 (1H, m, ArH), 7.42 (1H, m, ArH), 7.50 (1H,
m, ArH), 8.18 (1H, s, ArH), 8.22 (1H, s, ArH), 8.54 (1H, m, ArH),
14.2 ppm (1H, br s, COOH); LCMS (ES+): m/z (%): 332 (100)
[M+H]
+ (
79Br), 334 (100) [M+H]
+ (
81Br); tR=0.5–0.6 min.
8-Bromo-2-(5-methylfuran-2-yl)quinoline-4-carboxylic acid (32):
Prepared as for 27 from 7-bromoindoline-2,3-dione (1 g, 3.3 mm).
The crude product was triturated with hot Et2O to isolate purified
carboxylic acid 32 as a pale brown solid (400 mg, 41%):
1H NMR
and LCMS confirm purity at >95%;
1H NMR (500 MHz, [D6]DMSO):
d=2.42 (3H, s, CH3), 6.42 (1H, m, ArH), 7.39 (1H, d, J=3.3 Hz, ArH),
7.53 (1H, dd, J=8.4, 7.6 Hz, ArH), 8.2 (1H, dd, J=7.5, 1.1 Hz, ArH),
8.28 (1H, s, ArH), 8.62 (1H, dd, J=8.5, 1.1 Hz, ArH), 14.2 ppm (1H,
br s, COOH); LCMS (ES+): m/z (%): 332 (100) [M+H]
+ (
79Br), 334
(100) [M+H]
+ (
81Br); tR=0.5–0.6 min.
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Trypanothione Reductase as a Drug Target6-Bromo-2-(furan-2-yl)quinoline-4-carboxylic acid (33): 5-Bro-
moindoline-2,3-dione (1.25 g, 5 mm) and KOH flakes (2.8 g, 50 mm)
were added to a 30 mL microwave reactor tube containing EtOH/
H2O (20 mL, 1:1). The tube was transferred to the microwave reac-
tor and, following a 1 min prestirring, was heated to 1108C for
3 min. The tube was then removed from the reactor and 2-acetyl-
furan (0.6 g, 5.5 mm) was added. Heating in the microwave was re-
commenced (1108C for 12 min) to achieve complete reaction. The
reaction mixture was then acidified to pH 3 using AcOH, diluted
with H2O (60 mL) and extracted with EtOAc (2 80 mL). The organ-
ic layer was washed with H2O (2 80 mL) and brine (80 mL), dried
(MgSO4), filtered and concentrated to give a pale yellow solid. The
crude solid was heated to reflux in EtOAc (20 mL) and the remain-
ing insoluble cream solid was filtered off to give 33 (900 mg, 60%):
Product purity was determined by
1H NMR and LCMS as >98%;
RF=0.3 (10%, CH3OH/CH2Cl2);
1H NMR (500 MHz, [D6]DMSO): d=
6.77 (1H, m, ArH), 7.50 (1H, d, J=3.4 Hz, ArH), 7.97 (1H, dd, J=9.0,
2.1 Hz, ArH), 8.01 (2H, m, 2ArH), 8.38 (1H, s, ArH), 8.91 (1H, m,
ArH), 14.17 ppm (1H, br s, COOH); LCMS (ES+): m/z (%): 318
[M+H]
+; tR=0.5–0.6 min.
2-(5-Methylfuran-2-yl)quinoline-4-carboxylic acid (34): Prepared
as for 23 from indoline-2,3-dione (1 g, 6.79 mm), KOH flakes (3.8 g,
50 mm) and 2-acetyl-5-methylfuran (0.79 mL, 6.79 mm). The crude
solid was redissolved in refluxing EtOAc (30 mL) and the purified
product was precipitated out and filtered off, washing with cold
EtOAc (20 mL) to give compound 34 (500 mg, 31%): Product
purity was determined by
1H NMR and LCMS as >98%; RF=0.15
(10%, CH3OH/CH2Cl2);
1H NMR (500 MHz, [D6]DMSO): d=2.42 (3H,
br s, CH3), 6.38 (1H, m, ArH), 7.36 (1H, d, J=3.3 Hz, ArH), 7.62 (1H,
ddd, J=8.2, 6.9, 1.2 Hz, ArH), 7.79 (1H, ddd, J=8.4, 6.9, 1.4 Hz,
ArH), 7.87 (1H, s, ArH), 8.02 (1H, d, J=8.4 Hz, ArH), 8.11 ppm (1H,
m, ArH); LCMS (ES+): m/z (%): 254 [M+H]
+; tR=0.5–0.6 min.
1-Methyl-6-(1-methylhydrazinyl)pyrimidine-2,4-(1H,3H)dione
(35): 6-Chloro-3-methyluracil (2.0 g, 12.5 mmol) and methyl-hydra-
zine (0.861 mL, 16.2 mmol) were refluxed in EtOH (20 mL) for 1.5 h.
The reaction was cooled to RT and concentrated in vacuo to afford
pyrimidine 35 as a pale yellow solid (1.96 g, 100%):
1H NMR
(500 MHz, [D6]DMSO): d=2.67 (1H, br s, NH), 3.09 (3H, s, CH3), 3.11
(3H, s, CH3), 3.41 (2H, br s, NH2), 4.23 ppm (1H, s, CH); LCMS (ES+
): m/z (%): 288 [M+H]
+ (100); tR=2.7–2.9 min.
6-(2-(5-Bromo-2-fluorobenzylidene)-1-methylhydrazinyl)-1-meth-
ylpyrimidine-2,4(1H,3H)dione (36): Compound 35 (1.0 g,
4.07 mmol) and 5-bromo-2-fluoro-benzaldehyde (0.959 mL,
4.07 mmol) were refluxed in EtOH (40 mL) for 2 h. The reaction was
cooled to RT, filtered and washed with Et2O to afford benzylidene
36 as a cream solid (1.61 g, 100%):
1H NMR (500 MHz, [D6]DMSO):
d=3.13 (2H, s, CH3), 3.39 (3H, s, CH3), 5.31 (1H, d, J=2.3 Hz, CH),
7.28 (1H, dd, J=10.4, 8.8 Hz, ArH), 7.60 (1H, ddd, J=8.8, 4.6,
2.6 Hz, ArH), 7.88 (1H, s, NH), 8.74 (1H, dd, J=6.6, 2.6 Hz, ArH),
11.05 ppm (1H, d, J=2.3 Hz, imine CH); LCMS (ES+): m/z (%): 381
(100) [M+H]
+ (
79Br), 383 (100) [M+H]
+ (
81Br); tR=3.9 min.
3-(4-Bromo-2-fluorophenyl)-4-hydroxy-8-methyl-6,8-dihydropyri-
mido[5,4-e,1,2,4]triazine-5,7(1H,4H)dione (37): Benzylidene 36
(0.443 g, 1.22 mmol) was dissolved in AcOH/H20 (3.45/0.17 mL) and
the solution was cooled to 08C. NaNO2 (0.126 g, 1.83 mmol) was
added portionwise and the reaction was warmed to RT over 16 h.
Et2O (10 mL) was added and the reaction was stirred at RT for 1 h.
The resultant yellow precipitate was filtered and washed with Et2O
to afford 37 (0.460 g, 99%):
1H NMR (500 MHz, [D6]DMSO): d=3.25
(3H, s, CH3), 7.39 (1H, dd, J=10.6, 8.8 Hz, ArH), 7.72 (1H, ddd, J=
8.8, 4.1, 2.7 Hz, ArH), 8.11 (1H, dd, J=6.8, 2.7 Hz, ArH), 12.30 ppm
(1H, br s, OH).
3-(5-Bromo-2-fluorophenyl)-6-methylpyrimido[5,4-e,1,2,4]tri-
azine-5,7(1H,6H)dione (42): Compound 37 (0.430 g, 1.12 mmol)
was heated in anhyd DMF (5 mL) at 908C for 2 h. The reaction was
cooled to RTand iced H2O was added. The resultant brown precipi-
tate was filtered and dried in vacuo to afford pyrimido triazine 42
(0.357 g, 91%):
1H NMR (500 MHz, [D6]DMSO): d=3.30 (3H, s, CH3),
7.48 (1H, dd, J=10.4, 8.9 Hz, ArH), 7.86 (1H, ddd, J=8.9, 4.1,
2.7 Hz, ArH), 8.15 (1H, dd, J=6.6, 2.7 Hz, ArH) and 13.00 ppm (br s,
1H, NH); LCMS (ES+): m/z (%): 351 (100) [M+H]
+ (
79Br), 353 (100)
[M+H]
+ (
81Br); tR=3.9 min.
3-(5-Bromo-2-fluorophenyl)pyrimido[5,4-e,1,2,4]triazine-
5,7(1H,6H)dione (43): 3-(5-Bromo-2-fluorophenyl)-4-hydroxy-1-
methyl-6,8-dihydropyrimido[5,4-e][1,2,4]triazine-5,7(1H,4H)-dione
(0.430 g, 1.12 mmol) was heated in anhyd DMF (5 mL) at 908C for
3 h in a sealed tube with 4   molecular sieves. The reaction was
cooled to RTand iced H2O was added. The resultant brown precipi-
tate was filtered and dried in vacuo to afford pyrimido triazine 43
(48 mg, 77%):
1H NMR (500 MHz, [D6]DMSO): d=7.29 (1H, dd, J=
5.0, 3.7 Hz, ArH), 7.86 (1H, ddd, J=5.0, 1.2 Hz, ArH), 8.01 (1H, dd,
J=3.7, 1.2 Hz, ArH), 11.97 (1H, br s, NH), 12.49 ppm (1H, br s, NH).
3-(5-Bromo-2-fluorophenyl)-1-((2-dimethylamino)ethyl)-6-meth-
ylpyrimido[5,4-e,1,2,4]triazine-5,7(1H,6H)dione (48): Compound
42 (50 mg, 0.14 mmol), Cs2CO3 (97 mg, 0.30 mmol), 2-dimethylami-
noethylchloride (20 mg, 0.14 mmol) and anhyd DMF (2 mL) were
heated at 808C for 3 h. The reaction mixture was then filtered and
diluted with EtOAc, the organic layer was washed with H2O( 3  
10 mL), dried (MgSO4), filtered and concentrated in vacuo. The
crude was purified by column chromatography (CH2Cl2/MeOH/NH3,
95:5:0.1) to give pyrdimido triazine 48 as a yellow solid (5 mg,
9%):
1H NMR (500 MHz, CDCl3): d=2.11 (6H, br s, 2CH3), 2.80 (2H,
br s, CH2), 3.48 (3H, s, CH3), 4.13 (2H, t, J=6.2 Hz, CH2), 7.04 (1H,
dd, J=10.3, 8.8 Hz, ArH), 7.49 (1H, ddd, J=8.8, 4.2, 2.6 Hz, ArH,),
8.13 ppm (1H, dd, J=6.6, 2.6 Hz, ArH); LCMS (ES+): m/z (%): 395
(100) [M+H]
+ (
79Br), 397 (100) [M+H]
+ (
81Br); tR=0.9–1.1 min.
3-(5-Bromo-2-fluorophenyl)-1-isopropyl-6-methylpyrimido[5,4-
e,1,2,4]triazine-5,7(1H,6H)dione (50): Compound 42 (50 mg,
0.14 mmol), Cs2CO3 (97 mg, 0.30 mmol), isopropylbromide
(0.015 mL, 0.14 mmol) and anhyd DMF (2 mL) were heated at
1508C for 10 min in a Biotage microwave reactor. The reaction mix-
ture was filtered and the filtrate was concentrated in vacuo. The
crude was purified by column chromatography (CH2Cl2/MeOH/NH3,
95:5:0.1) to give pyrdimido triazine 50 as a yellow solid (5 mg,
9%):
1H NMR (500 MHz, CDCl3): d=8.35 (1H, dd, J=6.6, 2.6 Hz,
ArH), 7.65 (1H, ddd, J=8.8, 4.2, 2.6 Hz, ArH), 7.18 (1H, dd, J=10.3,
8.8 Hz, ArH,), 5.90 (1H, sep, J=7.0 Hz, CH), 3.57(3H, s, CH3),
1.72 ppm (6H, d, J=7.0 Hz, isopropy-CH3); LCMS (ES+): m/z (%):
399 (100) [M+H]
+ (
79Br), 401 (100) [M+H]
+ (
81Br); tR=4.8 min.
3-(5-Bromo-2-fluorophenyl)-1-butyl-6-methylpyrimido[5,4-
e,1,2,4]triazine-5,7(1H,6H)dione (51): Compound 42 (50 mg,
0.14 mmol), Cs2CO3 (69 mg, 0.21 mmol), n-butylbromide (0.015 mL,
0.14 mmol) and anhyd DMF (2 mL) were heated at 808C for 6 h.
The reaction mixture was filtered and the filtrate was concentrated
in vacuo. The crude was purified by column chromatography
(hexane/Et2O, 9:1) to give pyrdimido triazine 51 as a yellow solid
(5 mg, 9%):
1H NMR (500 MHz, CDCl3): d=8.33 (1H, dd, J=6.6,
2.6 Hz, ArH), 7.53 (1H, ddd, J=8.7, 4.2, 2.6 Hz, ArH), 7.16 (1H, dd,
J=10.2, 8.8 Hz, ArH,), 4.53 (2H, t, J=7.7 Hz, CH2), 3.56 (3H, s, CH3),
1.81–1.78 (2H, m, CH2), 1.50–1.43 (2H, m, CH2) and 1.00–0.97 ppm
(3H, m, CH3).
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e,1,2,4]triazine-5,7(1H,6H)dione (52): Compound 42 (50 mg,
0.14 mmol), K2CO3 (40 mg, 0.29 mmol), cyclopentylbromide
(0.020 mL, 0.14 mmol) and anhyd DMF (2 mL) were heated at
1508C for 10 min in a Biotage microwave reactor. The reaction mix-
ture was filtered and the filtrate concentrated in vacuo. The crude
was purified by column chromatography (CH2Cl2/MeOH/NH3
95:5:0.1) to give pyrdimido triazine 52 as a yellow solid (5 mg,
9%):
1H NMR (500 MHz, CDCl3): d=8.19 (1H, dd, J=6.7, 2.6 Hz,
ArH), 7.54 (1H, ddd, J=8.8, 4.2, 2.6 Hz, ArH), 7.11 (1H, dd, J=10.4,
8.8 Hz, ArH,), 4.96 (1H, m, cyclopentyl CH), 3.51 (3H, s, CH3), 2.36–
2.31 (2H, m, cyclopentyl CH2), 2.09–2.03 (4H, m, cyclopentyl CH2)
and 1.73–1.65 ppm (2H, m, cyclopentyl CH2).
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